ImmunityBio, Inc. (IBRX)
NASDAQ·Healthcare·Biotechnology
$6.98
-4.32%
Mkt Cap $8.30B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 23, 2026 | $38.36M | $38.28M | -0.20% | -$0.08 | -$0.06 | +25.00% | — | — |
| Q4 2025 Nov 4, 2025 | $37.78M | $32.06M | -15.14% | -$0.10 | -$0.07 | +30.00% | — | — |
| Q3 2025 Aug 5, 2025 | $31.88M | $26.43M | -17.12% | -$0.10 | -$0.10 | +0.00% | — | — |
| Q2 2025 May 12, 2025 | $16.60M | $16.52M | -0.50% | -$0.12 | -$0.15 | -25.00% | — | — |
| Q1 2025 Mar 3, 2025 | $9.63M | $7.55M | -21.54% | -$0.26 | -$0.15 | +42.31% | — | — |
| Q4 2024 Nov 12, 2024 | $9.07M | $6.11M | -32.69% | -$0.18 | -$0.14 | +22.22% | — | — |
| Q3 2024 Aug 12, 2024 | $2.52M | $1.05M | -58.45% | -$0.17 | -$0.20 | -17.65% | — | — |
| Q2 2024 May 9, 2024 | $20.00K | $40.00K | +100.00% | -$0.16 | -$0.20 | -25.00% | — | — |
| Q1 2024 Mar 19, 2024 | $20.00K | $139.00K | +595.00% | -$0.18 | -$0.19 | -5.56% | — | — |
| Q4 2023 Nov 8, 2023 | $20.00K | $82.00K | +310.00% | -$0.27 | -$0.19 | +29.63% | — | — |
| Q3 2023 Aug 8, 2023 | $360.00K | $41.00K | -88.61% | -$0.26 | -$0.28 | -7.69% | — | — |
| Q2 2023 May 11, 2023 | $360.00K | $360.00K | +0.00% | -$0.27 | -$0.27 | +0.00% | — | — |
| Q1 2023 Mar 1, 2023 | $25.00K | $73.00K | +192.00% | -$0.22 | -$0.27 | -22.73% | — | — |
| Q4 2022 Nov 9, 2022 | $118.00K | $118.00K | +0.00% | -$0.23 | -$0.28 | -21.74% | — | — |
| Q3 2022 Aug 8, 2022 | $25.00K | $35.00K | +40.00% | -$0.24 | -$0.24 | +0.00% | — | — |
| Q2 2022 May 10, 2022 | $25.00K | $14.00K | -44.00% | -$0.22 | -$0.26 | -18.18% | — | — |
| Q1 2022 Mar 2, 2022 | $25.00K | $390.00K | +1460.00% | -$0.21 | -$0.23 | -9.52% | — | — |
| Q4 2021 Nov 12, 2021 | $20.00K | $66.00K | +230.00% | -$0.20 | -$0.22 | -10.00% | — | — |
| Q3 2021 Aug 12, 2021 | $235.97K | $339.00K | +43.66% | -$0.12 | -$0.23 | -91.67% | — | — |
| Q2 2021 May 14, 2021 | $186.12K | $139.00K | -25.32% | -$0.41 | -$0.21 | +48.78% | — | — |